Centessa Pharmaceuticals plc
CNTA
$16.44
-$0.56-3.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.34M | -26.14M | -111.33M | -42.57M | -43.82M |
| Total Depreciation and Amortization | 226.00K | 217.00K | 90.00K | 82.00K | 236.00K |
| Total Amortization of Deferred Charges | 293.00K | 312.00K | 140.00K | 154.00K | -- |
| Total Other Non-Cash Items | 8.92M | 6.80M | 43.12M | 8.91M | 8.88M |
| Change in Net Operating Assets | 18.45M | -38.44M | 25.18M | 12.03M | -5.88M |
| Cash from Operations | -22.45M | -57.25M | -42.80M | -21.39M | -40.58M |
| Capital Expenditure | -126.00K | -- | 0.00 | -34.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.83M | -222.39M | 25.00M | 45.00M | -55.46M |
| Cash from Investing | -39.95M | -222.39M | 25.00M | 44.96M | -55.46M |
| Total Debt Issued | -- | -- | 109.34M | -- | -- |
| Total Debt Repaid | -- | -- | -110.10M | -- | -- |
| Issuance of Common Stock | 1.71M | 7.87M | 5.31M | 246.95M | 108.07M |
| Repurchase of Common Stock | -4.49M | -- | -- | -- | -2.76M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4.39M | -4.79M | -1.59M | -970.00K | -- |
| Cash from Financing | 1.61M | 3.09M | 2.96M | 245.98M | 105.31M |
| Foreign Exchange rate Adjustments | -113.00K | -1.52M | 3.03M | -1.90M | -120.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.91M | -278.07M | -11.81M | 267.65M | 9.15M |